HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

XR 300

structure in first source

Also Known As:

ethyl N(beta)-(2-(3-(4-formamidinophenyl)isoxazolin-5(R)-yl)acetyl)-2,3-(S)-diaminopropionate

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Isoxazoles: 155
      - XR 300: 5

Experts

1.	Gao, Keming: 2 articles (03/2020 - 08/2011)
2.	Tecco, Juan Martin: 1 article (09/2020)
3.	Tecco, Simona: 1 article (09/2020)
4.	Bai, Yuanhan: 1 article (03/2020)
5.	Chen, Guanjie: 1 article (03/2020)
6.	Yang, Haichen: 1 article (03/2020)
7.	Fudala, Paul J: 1 article (01/2019)
8.	Garofalo, Amanda S: 1 article (01/2019)
9.	Greenwald, Mark K: 1 article (01/2019)
10.	Haight, Barbara R: 1 article (01/2019)

Related Diseases

1.	Bipolar Disorder (Manic Depressive Psychosis) 08/01/2011 - "For quetiapine-XR 300 mg/d, the NNTHs for discontinuation due to adverse events were 9 for bipolar depression, 8 for refractory MDD, 9 for MDD, and 5 for GAD. " 03/01/2020 - "For somnolence, pooled NNH was from 5 with carbamazepine to 23 with cariprazine in mania, 3 with quetiapine-XR 300 mg/d to 79 with lurasidone in bipolar depression, and 11 with olanzapine to -49 with aripiprazole in maintenance. "
2.	Schizophrenia (Dementia Praecox) 12/01/2007 - "Rapid dose escalation of quetiapine XR (300 mg on day 1,600 mg on day 2, and 800 mg on day 3) was also well tolerated, with a therapeutically effective dose reached by day 2. Clinically stable patients with schizophrenia receiving quetiapine IR (400-800 mg/day) can be switched to an equivalent once-daily dose of quetiapine XR (400-800 mg/day once-daily) without clinical deterioration or compromise in tolerability. "
3.	Pruritus (Itching) 01/01/2019 - "The most common adverse events were headache (17 [8%] participants in the BUP-XR 300 mg/300 mg group vs 19 [9%] participants in the BUP-XR 300 mg/100 mg group vs six [6%] participants in the placebo group), constipation (16 [8%] vs 19 [9%] vs 0), nausea (16 [8%] vs 18 [9%] vs five [5%]), and injection-site pruritis (19 [9%] vs 13 [6%] vs four [4%]). "
4.	Nausea 01/01/2019 - "The most common adverse events were headache (17 [8%] participants in the BUP-XR 300 mg/300 mg group vs 19 [9%] participants in the BUP-XR 300 mg/100 mg group vs six [6%] participants in the placebo group), constipation (16 [8%] vs 19 [9%] vs 0), nausea (16 [8%] vs 18 [9%] vs five [5%]), and injection-site pruritis (19 [9%] vs 13 [6%] vs four [4%]). "
5.	Headache (Headaches) 01/01/2019 - "The most common adverse events were headache (17 [8%] participants in the BUP-XR 300 mg/300 mg group vs 19 [9%] participants in the BUP-XR 300 mg/100 mg group vs six [6%] participants in the placebo group), constipation (16 [8%] vs 19 [9%] vs 0), nausea (16 [8%] vs 18 [9%] vs five [5%]), and injection-site pruritis (19 [9%] vs 13 [6%] vs four [4%]). "

Related Drugs and Biologics

1.	Quetiapine Fumarate (Seroquel)
2.	Bupropion (Wellbutrin)
3.	Carbamazepine (Tegretol)
4.	Olanzapine (Zyprexa)
5.	Lurasidone Hydrochloride
6.	Aripiprazole (Abilify)
7.	cariprazine